A Study of the Cardiac Effects of ALXN2050 in Healthy Adults

Study Identifier:
ALXN2050-HV-107
ClinicalTrials.gov Identifier:
NCT04660890
EudraCT Identifier:
N/A
Sponsor:
Alexion Pharmaceuticals, Inc.
Study Contact Information:
N/A
Study Complete

Study Details

Medical Condition
  • Other
Study Drug
  • Drug: ALXN2050
  • Drug: ALXN2050-matching Placebo
  • Drug: Moxifloxacin
  • Drug: Moxifloxacin-matching Placebo
Date
Dec 2020 - Mar 2021
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 55 Years
Requirements Information
Sex
Female & Male
Age
18 - 55 Years

Study Details

Medical Condition
  • Other
Study Drug
  • Drug: ALXN2050
  • Drug: ALXN2050-matching Placebo
  • Drug: Moxifloxacin
  • Drug: Moxifloxacin-matching Placebo
Date
Dec 2020 - Mar 2021
Phase 1
Phase 2
Phase 3
Phase 4
N/A
Patient Requirements
Sex: Female & Male
Age: 18 - 55 Years years
Requirements Information

Protocol Summary

This is a randomized, double-blind, double-dummy, placebo- and positive-controlled parallel study to evaluate the effect of ALXN2050 on the QT interval in healthy adult participants.

Trial Locations

Location
Status
Location
Clinical Trial Site
Tempe, Arizona, United States, 85283
Status
N/A